Amica Mutual Insurance Co. Sells 5,806 Shares of Johnson & Johnson $JNJ

Amica Mutual Insurance Co. lowered its stake in shares of Johnson & Johnson (NYSE:JNJ) by 11.9% in the second quarter, according to its most recent disclosure with the SEC. The fund owned 42,783 shares of the company’s stock after selling 5,806 shares during the period. Amica Mutual Insurance Co.’s holdings in Johnson & Johnson were worth $6,535,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. GFG Capital LLC acquired a new position in shares of Johnson & Johnson in the 2nd quarter worth approximately $35,000. Stone House Investment Management LLC acquired a new stake in Johnson & Johnson in the 1st quarter valued at $47,000. 1248 Management LLC bought a new stake in Johnson & Johnson in the first quarter valued at $48,000. Harvest Fund Management Co. Ltd acquired a new position in Johnson & Johnson during the first quarter worth $52,000. Finally, Pandora Wealth Inc. bought a new position in shares of Johnson & Johnson during the first quarter valued at $65,000. 69.55% of the stock is owned by institutional investors.

Johnson & Johnson Trading Down 0.3%

NYSE JNJ opened at $186.50 on Friday. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $194.48. The stock has a 50-day simple moving average of $184.25 and a 200 day simple moving average of $168.70. The company has a current ratio of 1.07, a quick ratio of 0.80 and a debt-to-equity ratio of 0.50. The company has a market capitalization of $449.34 billion, a PE ratio of 18.00, a P/E/G ratio of 2.19 and a beta of 0.38.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share (EPS) for the quarter. The company had revenue of $24.02 billion during the quarter. Johnson & Johnson had a return on equity of 32.73% and a net margin of 27.26%. Research analysts forecast that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 9th. Shareholders of record on Tuesday, November 25th will be paid a $1.30 dividend. This represents a $5.20 annualized dividend and a yield of 2.8%. The ex-dividend date of this dividend is Tuesday, November 25th. Johnson & Johnson’s dividend payout ratio is presently 50.19%.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on JNJ shares. Daiwa Capital Markets raised shares of Johnson & Johnson from a “neutral” rating to an “outperform” rating and set a $203.00 target price on the stock in a report on Monday, October 20th. Citigroup upped their price objective on shares of Johnson & Johnson from $213.00 to $215.00 and gave the stock a “buy” rating in a research note on Wednesday, October 15th. UBS Group lifted their target price on shares of Johnson & Johnson from $190.00 to $214.00 and gave the company a “buy” rating in a research note on Tuesday, October 14th. Royal Bank Of Canada restated an “outperform” rating and set a $209.00 price target on shares of Johnson & Johnson in a research report on Friday, October 10th. Finally, Wall Street Zen upgraded Johnson & Johnson from a “hold” rating to a “buy” rating in a research report on Saturday, September 13th. Three equities research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $199.05.

Insider Buying and Selling at Johnson & Johnson

In other news, EVP Jennifer L. Taubert sold 56,471 shares of the business’s stock in a transaction on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the transaction, the executive vice president owned 178,013 shares of the company’s stock, valued at $31,652,491.53. The trade was a 24.08% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.16% of the stock is currently owned by corporate insiders.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.